Association of Platelet-Activating Factor with Primary Acquired Cold Urticaria

New England Journal of Medicine

Volumn 313, Issue 7, 1985, Pages 405-409

  Grandel, Karen E ^a,b   Farr, Richard S ^a,b   Wanderer, Alan A ^a,b   Eisenstadt, Thomas C ^a,b   Wasserman, Stephen I ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXEPIN; HISTAMINE; RADIOISOTOPE; SEROTONIN H 3; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANIMAL CELL; ARTICLE; BLOOD AND HEMOPOIETIC SYSTEM; CHEMOTAXIS; CLINICAL ARTICLE; COLD URTICARIA; COLD WATER; DIAGNOSIS; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG RECEPTOR BINDING; ETIOLOGY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MEDIATOR; NEUTROPHIL; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PRIORITY JOURNAL; TEMPERATURE; THERAPY;

EID: 0021889497     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198508153130702     Document Type: Article

References (34)

1. Demopoulos CA, Pinckard RN. Hanahan DJ. Platelet-activating factor: evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholinc as the active component (a new class of lipid chemical mediators). J Biol Chem 1979; 254: 9355–8.
2. Benveniste J, Tencé M, Varenne P, Bidault J, Boullet C, Polonsky J. Semisynthèse et structure proposée du facteur activant les plaquettes (PAF): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Acad Sci (D) 1979; 289: 1037–40.
3. Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun 1979; 90: 1194–200.
4. Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils, and a platelet-activating factor. J Exp Med 1972; 136: 1356–77.
5. Pinckard RN. Platelet-activating factor. Hosp Pract 1983; 18(11):67–76.
6. Pinckard RN, Farr RS, Hanahan DJ. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE-sensitive basophils. J Immunol 1979; 123: 1847–57.
7. Archer CB, Page CP, Paul W, Morley J, MacDonald DM. Inflammatory characteristics of platelet activating factor (PAF-acether) in human skin. Br J Dermatol 1984; 110: 45–50.
8. Lotner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet activating factor. J Immunol 1980; 124: 676–84.
9. Betz SJ, Henson PM. Production and release of platelet-activating factor (PAF): dissociation from degranulation and Superoxide production in the human neutrophil. J Immunol 1980; 125: 2756–63.
10. Clark PO, Hanahan DJ, Pinckard RN. Physical and chemical properties of platelet-activating factor obtained from human neutrophils and monocytes and rabbit neutrophils and basophils. Biochim Biophys Acta 1980; 628: 69–75.
11. Arnoux B, Duval D, Benveniste J. Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A 23187 and phagocytosis. Eur J Clin Invest 1980; 10: 437–41.
12. Camussi G, Mencia-Huerta JM, Benveniste J. Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement, and neutrophils on human and rabbit mastocytes and basophils. Immunology 1977; 33: 523–34.
13. Camussi G, Aglietta M, Malavasi F, Bussolino F, Piacibello W, Sanavio F, Tetta C. Release of platelet-activating factor from human endothelial cells. In: Benveniste J, Arnoux B, eds. Platelet activating factor. Amsterdam: Elsevier, 1983:83–90. (INSERM symposium no. 23).
14. Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979; 279: 799–800.
15. Lee T, Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human cosinophils. J Biol Chem 1984; 259: 5526–30.
16. Rose B. Studies on blood histamine in cases of allergy. I. Blood histamine during wheal formation. J Allergy 1941; 12: 327–34.
17. Kaplan AP, Gray L, Shaff RE, Horakova Z, Beaven MA. In vivo studies of mediator release in cold and cholinergic urticaria. J Allergy Clin Immunol 1975; 55: 394–402.
18. Wasserman SI, Austen KF, Soter NA. The functional and physiochemical characterization of three eosinophilotactic activities released into the circulation by cold challenge of patients with cold urticaria. Clin Exp Immunol 1982; 47: 570–8.
19. Wasserman SI, Soter NA, Center DM, Austen KF. Cold urticaria: recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge. J Clin Invest 1977; 60: 189–96.
20. Wasserman SI, Ginsberg MH. Release of platelet factor 4 into the blood after cold challenge of patients with cold urticaria. J Allergy Clin Immunol 1984; 74: 275–9.
21. Cox CP, Wardlow ML, Jorgensen R, Farr RS. The presence of platelet-activating factor (PAF) in normal human mixed saliva. J Immunol 1981; 127: 46–50.
22. Farr RS, Wardlow ML.Cox CP, Meng KE, Greene DE. Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. Fed Proc 1983; 42: 3120–2.
23. Cox CP, Wardlow ML, Meng KE, Greene DR, Farr RS. Substrate specificity of the phosphatide 2-acylhydrolase that inactivates AGEPC. In: Benveniste J, Arnoux B, eds. Platelet activating factor. Amsterdam: Elsevier, 1983:299–304. (INSERM symposium no. 23).
24. Goetzl EJ, Kaplan AP. Lipid and peptide mediators of inflammation: summary. Fed Proc 1983; 42: 3119.
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911–7.
26. Cox CP, Wardlow ML, Jorgensen R, Farr RS. A substance similar to platelet activating factor in human blood. Fed Proc 1980; 39: 693. abstract
27. Wanderer AA, St. Pierre J-P, Ellis EF. Primary acquired cold urticaria: double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol 1977; 113: 1375–7.
28. Petillo JJ, Natbony SF, Zisblatt M, Vukovich RA, Neiss ES, Kaplan AP. Preliminary report of the effects of tiaramide on the ice cube test in patients with idiopathic cold urticaria. Ann Allergy 1983; 51: 511–4.
29. Sigler RW, Evans R III, Horakova A, Ottesen E, Kaplan AP. The role of cyproheptadine in the treatment of cold urticaria. J Allergy Clin Immunol 1980; 65: 309–12.
30. Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc 1979; 54: 669–74.
31. Black AK, Keahey TM, Eady RAJ, Greaves M.-W. Dissociation of histamine release and clinical improvement following treatment of acquired cold urticaria by prednisone. Br J Clin Pharmacol 1981; 12: 327–31.
32. Horton BT, Brown GE, Roth GM. Hypersensitivities to cold: with local and systemic manifestations of a histamine-like character: its amenability to treatment. JAMA 1936; 107: 1263–9.
33. McManus LM, Pinchard RN, Fitzpatrick FA, O'Rourke RA, Crawford MH, Hanahan DJ. Acetyl glyceryl ether phosphorylcholine: intravascular alterations following intravenous infusion into the baboon. Lab Invest 1981; 45: 303–7.
34. Pinckard RN, McManus LM, O'Rourke RA, Crawford MH, Hanahan DJ. Intravascular & cardiovascular effects of acetyl glyceryl ether phosphorylcholine infusion in the baboon. Clin Res 1980; 28: 358A.